A Multicenter Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial to Determine the Antiviral Activity, Pharmacokinetics, Tolerability and Safety of RDEA806 in HIV-1 Positive, Antiretroviral naive Subjects.

Trial Profile

A Multicenter Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial to Determine the Antiviral Activity, Pharmacokinetics, Tolerability and Safety of RDEA806 in HIV-1 Positive, Antiretroviral naive Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2013

At a glance

  • Drugs RDEA 806 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Ardea Biosciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2010 Results have been published in Antimicrobial Agents and Chemotherapy.
    • 25 Oct 2008 Results were presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America - A Joint Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top